Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 687.07

+1.8%

11:00 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2836)	1/30/2020 2:31:08 AM
From: Miljenko Zuanic	of 3557

PS: Lucentis 4Q US sale were .... 456m SCF, or $469.6m (1.03 exchange rate) , which is in line with 1/2Q-2019 and bit better than 3Q. 4Q is usually strongest for part B drugs, MDs baying ahead for next year so they can shed more on taxes. This make Beovu $35 m even stranger, so I will pesume large part (>50%) was on inventory. Will see how will REGN defend and respond to this development. Keep in mind, IF high-dose Eylea formulation fare well,REGN will have 9by 2023) dosing interval flexibility as well as dose strength flexibility ( 2 to 8 mg, pts subjective dose).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next